Home/Resources/Vesicle Assay vs. ATPase Assay
DMPK Science · Assay Selection · Cell4Pharma
Both are established, both appear in regulatory submissions — and both produce false negatives that are easy to miss. A direct comparison.
Both assays use membrane preparations from cells overexpressing an ABC transporter. Both are established, both appear in regulatory submissions, and most transporter vendors offer both. That similarity causes a recurring problem in screening cascade design: the two methods measure different things and fail in different ways.
Choosing the wrong one produces false negatives that are easy to miss, because a negative result in either assay looks identical on paper.
What Each Assay Actually Measures
The vesicular transport assay measures transport. Inside-out vesicles accumulate a probe substrate in an ATP-dependent manner. You quantify how much substrate ends up inside the vesicle. A test compound that reduces that accumulation is an inhibitor; a compound that accumulates itself is a substrate.
The ATPase assay measures ATP consumption. ABC transporters hydrolyse ATP as they cycle. The assay quantifies released inorganic phosphate, typically colorimetrically. A compound that stimulates ATPase activity is interacting with the transporter; a compound that suppresses baseline activity is interfering with the cycle.
The distinction matters: the vesicular assay observes the outcome, the ATPase assay observes the engine. Engine activity does not always translate into movement.
Side by Side
| Vesicular transport | ATPase | |
|---|---|---|
| Readout | Substrate accumulation inside vesicles | Inorganic phosphate release |
| Nature | Direct | Indirect |
| Substrate vs. inhibitor | Distinguishes clearly | Only partially |
| Throughput | Moderate to high (inhibition mode) | High |
| Detection | Radiolabel, fluorescence or LC-MS/MS | Plate reader (colorimetric) |
| Radiochemistry needed | Often | No |
| Main failure mode | High-permeability compounds escape the vesicle | Slowly transported compounds give no signal |
| Use for regulatory IC50 | Established | Supporting evidence |
Where the ATPase Assay Fails
The ATPase assay is fast, inexpensive and needs no radiochemistry infrastructure. Its weakness is specific and well documented.
Slowly transported substrates go undetected
Some compounds are transported so slowly that they generate no measurable increase in ATP hydrolysis above baseline, yet they are genuine substrates. Cyclosporin A is the standard example — unremarkable in the ATPase assay, clearly interacting in the vesicular assay.
High baseline activity masks weak effects
Certain transporters, P-gp in particular, show substantial constitutive ATPase activity. A modest stimulation can disappear into that noise.
The stimulation curve is not always interpretable
Responses come in several shapes — classical Michaelis-Menten, bell-shaped with high-concentration inhibition, flat, or suppressive. A bell-shaped curve can read as either substrate or inhibitor depending on the concentration range tested.
Where the Vesicular Assay Fails
The mirror-image weakness is passive permeability.
Vesicles are small and their membranes are lipid bilayers. A highly lipophilic, highly permeable compound transported into the vesicle diffuses straight back out before it can be measured. The compound is a genuine substrate; the assay reports nothing.
This is why substrate assays in the vesicular format are only reliable for compounds of low to moderate passive permeability. For a permeable compound you need a cell-based system — Caco-2, MDCK-MDR1 or a transfected line — where the transporter works across an intact polarised monolayer and efflux ratio is the readout.
Inhibition assays are far less affected. There the probe substrate is chosen for suitable permeability, and the test compound only has to reach the binding site. This is why vesicular inhibition assays are robust and widely used for IC50 determination, while vesicular substrate assays carry caveats.
Choosing
| Situation | Method |
|---|---|
| Early triage of large compound numbers, no radiochemistry facility | ATPase — but treat negatives with caution |
| IC50 for regulatory submission (BSEP, BCRP, P-gp, MRP family) | Vesicular transport |
| Substrate status of a high-permeability compound | Cell-based (Caco-2, MDCK-MDR1) |
| Modelling a polarised barrier — intestine, canaliculus, BBB | Cell-based |
| Renal transporter DDI (OAT1, OAT3, OCT2, MATE) | Cell-based — ciPTEC |
Most well-designed cascades use two of the three. A common pattern: ATPase for early triage, vesicular for IC50 confirmation on advanced compounds, cell-based for substrate determination where permeability rules out the vesicular format.
What Regulators Expect
ICH M12 (2023) harmonises FDA and EMA requirements for transporter-mediated drug interactions. For efflux transporters, P-gp and BCRP assessment is expected for new molecular entities.
The guidance does not mandate one assay format. In practice, IC50 values submitted for efflux transporter DDI assessment come predominantly from vesicular transport or cell-based efflux systems. ATPase data typically appears as supporting mechanistic evidence rather than as the primary determination.
If your data package will drive a DDI decision, generate it in the vesicular or cell-based format. Our overview of DMPK and ABC transporter assays maps which transporters are required for which submission type.
Practical Notes for the Vesicular Assay
- Always run control vesicles. ATP-dependent transport is the difference between transporter vesicles and non-transfected controls. Without the subtraction the number is not usable — see the Human Control Vesicle Kit.
- AMP is the correct negative condition, not ATP omission — it keeps the ionic environment comparable.
- Watch lot-to-lot transport ratios. The ATP/AMP ratio is the practical quality metric; a low ratio compresses the assay window and inflates IC50 variability.
- The expression system matters. Glycosylation and membrane lipid composition differ between host cells — see HEK293 vs. Sf9 vesicles.
- Match detection to the question. Radiolabel remains the reference for regulatory work, fluorescence suits screening, LC-MS/MS handles compounds that cannot be labelled.
Frequently Asked Questions
Can I use ATPase data in a regulatory submission?
As supporting mechanistic evidence, yes. As the primary IC50 determination for a DDI decision, it is not the expected format — reviewers look for vesicular or cell-based data.
Why did my compound show nothing in the ATPase assay but a clear effect in the vesicular assay?
Most likely a slowly transported substrate. It moves through the transporter without generating ATP hydrolysis above baseline. Cyclosporin A behaves this way. A negative ATPase result does not rule out interaction.
My compound is highly lipophilic. Can I still use the vesicular assay?
For inhibition studies, yes — the test compound only needs to reach the binding site. For substrate determination, no: it will diffuse back out of the vesicle before measurement. Use a cell-based efflux system instead.
Which transporters can be assessed in the vesicular format?
The efflux transporters: P-gp (ABCB1), BCRP (ABCG2), BSEP (ABCB11) and the MRP family (MRP1–MRP8). Uptake transporters such as OATP, OAT and OCT require cell-based systems.
Do I need radiochemistry infrastructure?
Not necessarily. Radiolabel remains the reference method, but fluorescent probe substrates are available for several transporters and work on a standard plate reader. LC-MS/MS is the third option for unlabelled compounds.
Related
HEK293 vs. Sf9 Vesicles →BSEP Inhibition & DILI →ABC Transporter Vesicle Kits →Human Control Vesicle Kit →ciPTEC Cell-Based Assays →SOLVO Alternative Compared →DMPK & ABC Transporter Assays →Assay Service →
Vesicle kits from EU stock
BSEP, BCRP, P-gp, MRP1–MRP8 and control vesicles — HEK293-derived, 100 reactions per kit, lot-specific activity data.Request a quote
English 
Deutsch